HIP1 Inhibitor Patent US12605456B2, Utah Valley University
Summary
The USPTO granted Patent US12605456B2 to Utah Valley University on April 21, 2026, covering inhibitor compounds that target the Huntingtin Interacting Protein 1 (HIP1) enzyme. The patented composition comprises a tripeptide targeting sequence directing the compound to HIP1's active site, conjugated to a C-terminal electrophilic warhead configured to inactivate the enzyme. The patent contains 20 claims.
“Provided herein is an inhibitor compound targeting Hip1, with the inhibitor compound comprising a tripeptide targeting sequence that directs the compound to the active site of Hip1 and a C-terminal electrophilic warhead conjugated to the targeting sequence, the warhead configured to inactive the enzyme.”
What changed
The USPTO issued US Patent US12605456B2 on April 21, 2026, granting Utah Valley University exclusive rights to compositions and methods for HIP1-targeting inhibitor compounds. The patented invention comprises a tripeptide targeting sequence linked to a C-terminal electrophilic warhead designed to inactivate the HIP1 enzyme. The patent is classified under CPC codes A61K 38/00, A61K 47/66, A61P 31/06, C07K 5/0812, C07K 7/06, and C07K 5/08, indicating therapeutic applications in anti-infective treatments.
Pharmaceutical companies and research institutions engaged in oncology or anti-infective drug development involving HIP1 pathways should evaluate whether the newly granted claims create any freedom-to-operate concerns or licensing opportunities. The patent's C07K classification in peptide chemistry may also be relevant to firms developing peptide-based therapeutics with electrophilic warhead moieties.
Archived snapshot
Apr 21, 2026GovPing captured this document from the original source. If the source has since changed or been removed, this is the text as it existed at that time.
Composition and method for HIP1-targeting inhibitor compounds
Grant US12605456B2 Kind: B2 Apr 21, 2026
Assignee
Utah Valley University
Inventors
Nathan E. Goldfarb, Andrew Abell, Nicholas Schumann, Borja Lopez Perez
Abstract
Provided herein is an inhibitor compound targeting Hip1, with the inhibitor compound comprising a tripeptide targeting sequence that directs the compound to the active site of Hip1 and a C-terminal electrophilic warhead conjugated to the targeting sequence, the warhead configured to inactive the enzyme.
CPC Classifications
A61K 38/00 A61K 47/66 A61P 31/06 C07K 5/0812 C07K 7/06 C07K 5/08
Filing Date
2022-05-28
Application No.
17827700
Claims
20
Mentioned entities
Parties
Related changes
Get daily alerts for USPTO Patent Grants - Therapeutics (A61P)
Daily digest delivered to your inbox.
Free. Unsubscribe anytime.
Source
About this page
Every important government, regulator, and court update from around the world. One place. Real-time. Free. Our mission
Source document text, dates, docket IDs, and authority are extracted directly from USPTO.
The summary, classification, recommended actions, deadlines, and penalty information are AI-generated from the original text and may contain errors. Always verify against the source document.
Classification
Who this affects
Taxonomy
Browse Categories
Get alerts for this source
We'll email you when USPTO Patent Grants - Therapeutics (A61P) publishes new changes.
Subscribed!
Optional. Filters your digest to exactly the updates that matter to you.